Autopsy report · NCT05083078

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The study was stopped due to unanticipated feasibility constraints.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 8 months before it stopped.
11 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Janssen Research & Development, LLC
Sponsor type: Industry
Conditions: Arthritis, Psoriatic; Healthy
Interventions: Guselkumab; Risankizumab
Participants: 11
Sites: 1
Countries: Austria

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.